Genfit (GNFT) has released an update.
GENFIT, a biopharmaceutical company focused on rare liver diseases, has filed its 2023 Universal Registration Document with the French AMF and its Annual Report with the U.S. SEC. These essential financial documents are publicly available on the company’s website and highlight GENFIT’s commitment to addressing high unmet medical needs in liver disease with its diverse pipeline of developmental programs. The company’s significant progress includes a successful 52-week Phase 3 trial for elafibranor in PBC and ongoing efforts to expand its diagnostic and therapeutic reach.
For further insights into GNFT stock, check out TipRanks’ Stock Analysis page.
